BACKGROUND: Recent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS). In this study, we aimed to assess the effects of aspirin use on outcomes in a predominantly Asian cohort of patients with CRC. PATIENTS AND METHODS: Case records of patients undergoing curative resection for stage I-III CRC were retrieved for clinical data and patterns of aspirin use and vital data were determined from hospital electronic prescription records, hospital pharmacy dispensing records, national clinical and prescription databases. CRC-specific and recurrence-free survival (RFS) amongst aspirin users and non-users were analyzed and compared using the Cox proportional hazards model. RESULTS: Out of 726 patients with CRC, 103 were regular aspirin users and 623 were non-users. The median age of the cohort was 65 years (range=22-94 years) and the majority of patients were Chinese (90%). Nineteen percent, 31% and 47% had stage I, II and III CRC respectively; tumor staging was unknown for 3%. After adjusting for prognostic factors (age, stage, lymph node stage, grade, lesion site, perineural invasion, lymphvascular invasion), the risk of CRC relapse or death from CRC was approximately 60% lower compared to patients who were not postoperative aspirin users (Hazard Ratio=0.38, 95% Confidence Interval=0.17-0.84, p=0.017). No benefit was observed for preoperative use of aspirin. CONCLUSION: In this single-Institution study, with long-term follow-up of patients with stage I-III-resected CRC, postoperative aspirin use was associated with reduced risk of relapse of and death from CRC. Copyright
BACKGROUND: Recent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS). In this study, we aimed to assess the effects of aspirin use on outcomes in a predominantly Asian cohort of patients with CRC. PATIENTS AND METHODS: Case records of patients undergoing curative resection for stage I-III CRC were retrieved for clinical data and patterns of aspirin use and vital data were determined from hospital electronic prescription records, hospital pharmacy dispensing records, national clinical and prescription databases. CRC-specific and recurrence-free survival (RFS) amongst aspirin users and non-users were analyzed and compared using the Cox proportional hazards model. RESULTS: Out of 726 patients with CRC, 103 were regular aspirin users and 623 were non-users. The median age of the cohort was 65 years (range=22-94 years) and the majority of patients were Chinese (90%). Nineteen percent, 31% and 47% had stage I, II and III CRC respectively; tumor staging was unknown for 3%. After adjusting for prognostic factors (age, stage, lymph node stage, grade, lesion site, perineural invasion, lymphvascular invasion), the risk of CRC relapse or death from CRC was approximately 60% lower compared to patients who were not postoperative aspirin users (Hazard Ratio=0.38, 95% Confidence Interval=0.17-0.84, p=0.017). No benefit was observed for preoperative use of aspirin. CONCLUSION: In this single-Institution study, with long-term follow-up of patients with stage I-III-resected CRC, postoperative aspirin use was associated with reduced risk of relapse of and death from CRC. Copyright
Authors: Ikuko Kato; Dorothy Lane; Catherine R Womack; Cathryn H Bock; Lifang Hou; Jennifer H Lin; Chunyuan Wu; Jennifer Beebe Dimmer; Michael S Simon Journal: J Am Coll Nutr Date: 2017-07-06 Impact factor: 3.169
Authors: Jeffrey A Meyerhardt; Qian Shi; Charles S Fuchs; Jeffrey Meyer; Donna Niedzwiecki; Tyler Zemla; Priya Kumthekar; Katherine A Guthrie; Felix Couture; Philip Kuebler; Johanna C Bendell; Pankaj Kumar; Dequincy Lewis; Benjamin Tan; Monica Bertagnolli; Axel Grothey; Howard S Hochster; Richard M Goldberg; Alan Venook; Charles Blanke; Eileen M O'Reilly; Anthony F Shields Journal: JAMA Date: 2021-04-06 Impact factor: 56.272
Authors: Jane C Figueiredo; Eric J Jacobs; Christina C Newton; Mark A Guinter; William G Cance; Peter T Campbell Journal: J Natl Cancer Inst Date: 2021-07-01 Impact factor: 13.506
Authors: Peter C Elwood; Gareth Morgan; Janet E Pickering; Julieta Galante; Alison L Weightman; Delyth Morris; Mark Kelson; Sunil Dolwani Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240
Authors: Jaqui Walker; Pippa Hutchison; Junbo Ge; Dong Zhao; Yongjun Wang; Peter M Rothwell; J Michael Gaziano; Andrew Chan; John Burn; John Chia; Ruth Langley; Valerie O'Donnell; Bianca Rocca; Chris Hawkey Journal: Ecancermedicalscience Date: 2018-02-20